Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Weight Loss of Oral Amycretin (NNC0487-0111) in Overweight or Obesity
NCT05369390Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- May 2022
- Primary completion
- Jan 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of amycretin in obesity and Overweight (8 arms), sponsored by Novo Nordisk. Primary endpoint: Treatment Emergent Adverse Events at Day 105. Started May 2022; status: completed.
02
Drugs
amycretin
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05369390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05369390.